CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold an aggregate of 21,607,878 shares of the ...

Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs ...

According to the note, the broker has retained its speculative buy rating and 25 cents price target on the ASX biotech stock.

Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%.

Healthcare Investors lagged its benchmark as biotech faced regulatory hurdles and market rotation. Read the full analysis for ...

Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

The 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E.

Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold an ...

Some proposed clinical trial rules could create hurdles for smaller countries while failing to ensure high quality and ...

Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on VIR. Vir Biotechnology, ...